2021-000508-39: A study to Evaluate the Safety, the Tolerability, the Pharmacokinetics and the Efficacy of HM15136 administered in pediatric Patients with Congenital Hyperinsulinism (CHI) |
|
|
| Not yet recruiting | 2 | 16 | Europe | HM15136, Solution for injection in pre-filled syringe | Hanmi Pharm. Co., Ltd., Hanmi Pharm. Co., Ltd. | Congenital Hyperinsulinism (CHI), Congenital hyperinsulinism is a disorder associated with severe, persistent hypoglycemia, characterized by excessive and dysregulated insulin secretion by the pancreatic β-cells., Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |